Ny homamiadan'ny prostate no homamiadana faharoa mahazatra indrindra amin'ny lehilahy manerantany, izay tombanana ho 1.276 tapitrisa ny tranga vaovao voatatitra tamin'ny taona 2018, izay maneho ny 7,1% amin'ny homamiadana rehetra amin'ny lehilahy.
Avo ihany koa ny taham-pahafatesana noho ny homamiadan'ny prostate, izay tombanana ho 37.005 no maty manerantany tamin'ny taona 2018.
Na izany aza, miovaova be ny taham-pahafatesana arakaraka ny faritra, miaraka amin'i Afrika Andrefana manana ny loza fahadimy avo indrindra amin'ny fahafatesan'ny homamiadan'ny prostate eto amin'izao tontolo izao, ary i Nizeria manana mponina sy toekarena lehibe indrindra ao amin'ity faritra ity.
Ao Nizeria, ny homamiadan'ny prostate no sady homamiadana mahazatra indrindra no mahafaty indrindra ny lehilahy, miaraka amin'ny tranga 32.8 sy fahafatesana 16.3 isaky ny lehilahy 100.000.
Mihoatra ny avo roa heny amin'ny taham-pahafatesana any Amerika Avaratra izany.
Ny fahataran'ny fahitana ny aretina, ny tsy fahampian'ny fitaovana hanaovana fitiliana sy ny fitadiavana, ary ny fihenan'ny antontan-taratasy sy ny fitaterana ny tranga dia mandray anjara amin'ny taha ambony amin'ny fahafatesana ao Nizeria.
Any Etazonia, ny homamiadan'ny prostate no antony faharoa mahazatra indrindra mahatonga ny fahafatesan'ny homamiadana amin'ny lehilahy, miaraka amin'ny lehilahy eo amin'ny 40.000 eo ho eo maty noho ny aretina isan-taona.
Nihena tsikelikely ny tahan'ny fahafatesan'ny homamiadan'ny prostate nanomboka tamin'ny fiandohan'ny taona 1990, saingy mbola olana lehibe eo amin'ny fahasalamana izany.
Amin'ny ankapobeny, aretina mahafaty ny homamiadan'ny prostate, indrindra any amin'ny faritra izay voafetra ny fahafahana mahazo fitsaboana sy fitaovana fitiliana.
Na izany aza, ny fitiliana sy ny fitsaboana mialoha dia afaka manatsara ny vokatra sy mampihena ny taham-pahafatesana.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Fialana andraikitra: fitsaboana']
['Natao hampianarana sy hampahafantarana fotsiny ity tranonkala ity, fa tsy natao hanomezana torohevitra ara-pitsaboana na tolotra matihanina.']
['Tsy tokony hampiasaina mba hamantarana na hitsaboana olana ara-pahasalamana na aretina ny fanazavana omena, ary tokony hanatona dokotera manana fahazoan-dalana hitsabo tena ireo mitady torohevitra ara-pitsaboana.']
["Mariho tsara fa ny tambajotra neural izay mamorona ny valin'ny fanontaniana, dia tsy marina indrindra raha resaka isa no resahina. Ohatra, ny isan'ny olona voamarina fa voan'ny aretina manokana."]
["Mitadiava torohevitra avy amin'ny dokotera na mpitsabo hafa mahay momba ny toe-pahasalamanao. Aza atao tsinontsinona mihitsy ny torohevitra ara-pitsaboana matihanina na manemotra ny fikatsahana azy noho ny zavatra novakianao tao amin'ity tranonkala ity. Raha mieritreritra ianao fa mety manana vonjy taitra ara-pitsaboana, antsoy ny 911 na mandehana any amin'ny efitrano fitsaboana maika akaiky indrindra avy hatrany. Tsy misy fifandraisana mpitsabo-marary noforonin'ity tranonkala ity na ny fampiasana azy. Na ny BioMedLib na ny mpiasa ao aminy, na ny mpandray anjara amin'ity tranonkala ity, dia tsy manao fanambarana, mazava na tsy mazava, momba ny fampahalalana omena eto na ny fampiasana azy."]
["Fanamarihana: zon'ny mpamorona"]
["Ny Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (ny DMCA) dia manome vahaolana ho an'ireo tompon'ny zon'ny mpamorona izay mino fa manitsakitsaka ny zony araka ny lalàna momba ny zon'ny mpamorona ao Etazonia ny fitaovana hita ao amin'ny Internet. "]
["Raha mino ianao fa misy votoaty na fitaovana azo ampiasaina amin'ny tranonkalanay na ny tolotra ataonay manitsakitsaka ny zon'ny mpamorona anao, dia afaka mandefa filazana aminay ianao (na ny mpandraharaha anao) mangataka ny hanesorana ny votoaty na ny fitaovana, na ny fanakanana ny fidirana amin'izany. "]
['Tsy maintsy alefa an-tsoratra amin\'ny alalan\'ny mailaka ny filazana (jereo ny fizarana "Contact" raha mila adiresy mailaka). ']
["Ny DMCA dia mitaky ny fampandrenesanao ny voalaza ho fanitsakitsahana ny zon'ny mpamorona ahitana ireto fampahalalana manaraka ireto: (1) famaritana ny asa voaaro zon'ny mpamorona izay voalaza fa voahitsakitsaka; (2) famaritana ny votoaty voalaza fa manitsakitsaka sy fampahalalana ampy ahafahantsika mahita ny votoatiny; (3) fampahalalana momba anao, anisan'izany ny adiresinao, nomeraon-telefaona ary adiresy mailaka; (4) fanambarana avy aminao fa mino tsara ianao fa ny votoaty amin'ny fomba nitarainana dia tsy nomen'ny tompon'ny zon'ny mpamorona alalana, na ny mpandraharahany, na amin'ny asan'ny lalàna rehetra; "]
["(5) fanambarana nosoniavinao, eo ambany sazin'ny fianianana diso, fa marina ny vaovao ao amin'ny fampahafantarana ary manana fahefana hampihatra ny zon'ny mpamorona izay voalaza fa voahitsakitsaka ianao; "]
["Mety hiteraka fahatarana amin'ny fikarakarana ny fitarainanao ny tsy fampidirana ireo vaovao rehetra voalaza etsy ambony."]
['Fifandraisana']
['Alefaso mailaka izahay raha misy fanontaniana / sosokevitra.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Manodidina ny']
['Mampiasa solosaina mandeha ho azy (algoritma fianarana milina) ny BioMedLib mba hamoronana fanontaniana sy valiny.']
["Manomboka amin'ny famoahana biomedika 35 tapitrisa ao amin'ny PubMed/Medline izahay. ary koa ny pejin'ny tranonkala RefinedWeb."]
